Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
Conditions: Biochemically Recurrent Prostate Carcinoma; Prostate Adenocarcinoma Interventions: Biological: Durvalumab; Drug: Olaparib; Other: Quality-of-Life Assessment; Other: Questionnaire Administration Sponsors: University of Washington; National Cancer Institute (NCI); AstraZeneca Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | AstraZeneca | Cancer | Cancer & Oncology | Carcinoma | Prostate Cancer | Research